Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 7/20 | 0.56 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8416503 | 0.83 | HTR1A (0.61) | SIGMAR1HTR7DRD2DRD3HTR1A | |
| SCHEMBL15748232 | 0.82 | SIGMAR1 (0.59) | SIGMAR1HTR7DRD2ADRA1ADRD3 | |
| SCHEMBL5848902 | 0.80 | OPRL1 (0.54) | SIGMAR1HTR7DRD2DRD3HTR1A | |
| SCHEMBL11465528 | 0.79 | SIGMAR1 (0.76) | SIGMAR1HTR7DRD2ADRA1ADRD3 | |
| SCHEMBL13875122 | 0.78 | SIGMAR1 (0.71) | SIGMAR1HTR7DRD2ADRA1ADRD3 | |
| SCHEMBL8128060 | 0.78 | SIGMAR1 (0.71) | SIGMAR1HTR7DRD2ADRA1ADRD3 | |
| SCHEMBL15748175 | 0.78 | SIGMAR1 (0.58) | SIGMAR1HTR7DRD2ADRA1ADRD3 | |
| SCHEMBL5847783 | 0.77 | HTR7 (0.51) | SIGMAR1HTR7 | |
| SCHEMBL8129982 | 0.77 | SIGMAR1 (0.70) | SIGMAR1HTR7DRD2ADRA1ADRD3 | |
| SCHEMBL13875120 | 0.77 | SIGMAR1 (0.69) | SIGMAR1HTR7DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0655248-B1 | Use of 1-4-4-aryl(or heteroaryl)-1-piperazinylbutyl-1H-azole derivatives for the preparation of medicaments for the treatment of disorders of gastric secretion | ESTEVE LABOR DR (ES) | 1999-09-15 | — | — | EP | claimed |
| US-5532234-A | Use of 1-[4-[4-aryl (or heteroaryl)-1-piperazinyl]-butyl)-1H-azole derivatives for the preparation of medicaments intended for the treatment of disorders of gastric secretion | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 1996-07-02 | — | — | US | claimed |
| EP-0655248-A1 | Use of 1-4-4-aryl(or heteroaryl)-1-piperazinylbutyl-1H-azole derivatives for the preparation of medicaments for the treatment of disorders of gastric secretion | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1995-05-31 | — | — | EP | claimed |
| EP-0808166-A1 | MEDICAMENT INTENDED TO THE TREATMENT OF OBSESSIVE COMPULSIVE TROUBLES, SLEEP APNOEA, SEXUAL DYSFUNCTIONS, EMESA AND TRANSPORT SICKNESS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1997-11-26 | — | — | EP | disclosed |
| WO-1997021439-A1 | MEDICAMENT INTENDED TO THE TREATMENT OF OBSESSIVE COMPULSIVE TROUBLES, SLEEP APNOEA, SEXUAL DYSFUNCTIONS, EMESA AND TRANSPORT SICKNESS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1997-06-19 | — | — | WO | disclosed |